−1.43 BMXN
299.71 KMXN
About BELLUS HEALTH INC
Sector
CEO
Roberto Bellini
Headquarters
Laval
Website
Employees (FY)
74
Founded
1993
ISIN
CA07987C2040
FIGI
BBG00PG37LY9
BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTA™, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™. KIACTA™ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. An investigational new drug application (IND) for a Phase 2/3 clinical study is expected to be filed with the U.S. Food and Drug Administration in 2016. In addition, BELLUS Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamab™ pre-clinical studies for the treatment of sHUS are currently underway. BELLUS Health’s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange BELLUS HEALTH INC stocks are traded under the ticker BLU/N.
BELLUS HEALTH INC is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
BLU/N earnings for the last quarter are −2.93 MXN whereas the estimation was −3.82 MXN which accounts for 23.50% surprise. Estimated earnings for the next quarter are −3.43 MXN. See more details about BELLUS HEALTH INC earnings.
BELLUS HEALTH INC revenue for the last quarter amounts to 78.02 K MXN despite the estimated figure of 68.27 K MXN. In the next quarter revenue is expected to reach 45.09 K MXN.
Yes, you can track BELLUS HEALTH INC financials in yearly and quarterly reports right on TradingView.
Like other stocks, BLU/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BELLUS HEALTH INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 74.00 employees. See our rating of the largest employees — is BELLUS HEALTH INC on this list?